Marre (ass) 2002

1 Treatments

**Studied treatment** metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) \( \leq 7 \) mmol/l

**Control treatment** metformin 500 mg,

**Concomittant treatments** -

2 Patients

**Patients** patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy

**Inclusion criteria** -

**Exclusion criteria** -

3 Methods

**Blinding** double-blind

**Design** Parallel groups

**Centers** multicentre

**Geographical area** -

**Sizes** -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References